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Background: Multimorbidity is highly prevalent in the elderly and relates to many adverse outcomes, such as
higher mortality, increased disability and functional decline. Many studies tried to reduce the heterogeneity of
multimorbidity by identifying multimorbidity clusters or disease combinations, however, the internal structure of
multimorbidity clusters and the linking between disease combinations and clusters are still unknown. The aim
of this study was to depict which diseases were associated with each other on person-level within the clusters
and which ones were responsible for overlapping multimorbidity clusters.
Methods: The study analyses insurance claims data of the Gmünder ErsatzKasse from 2006 with 43,632 female
and 54,987 male patients who were 65 years and older. The analyses are based on multimorbidity clusters from
a previous study and combinations of three diseases ("triads") identified by observed/expected ratios ≥ 2 and
prevalence rates ≥ 1%. In order to visualise a "disease network", an edgelist was extracted from these triads, which
was analysed by network analysis and graphically linked to multimorbidity clusters.
Results: We found 57 relevant triads consisting of 31 chronic conditions with 200 disease associations ("edges") in
females and 51 triads of 29 diseases with 174 edges in males. In the disease network, the cluster of cardiovascular
and metabolic disorders comprised 12 of these conditions in females and 14 in males. The cluster of anxiety,
depression, somatoform disorders, and pain consisted of 15 conditions in females and 12 in males.
Conclusions: We were able to show which diseases were associated with each other in our data set, to which
clusters the diseases were assigned, and which diseases were responsible for overlapping clusters. The disease with
the highest number of associations, and the most important mediator between diseases, was chronic low back
pain. In females, depression was also associated with many other diseases. We found a multitude of associations
between disorders of the metabolic syndrome of which hypertension was the most central disease. The most
prominent bridges were between the metabolic syndrome and musculoskeletal disorders. Guideline developers
might find our approach useful as a basis for discussing which comorbidity should be addressed.
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Multimorbidity is the presence of multiple chronic con-
ditions that can include any type of disease combina-
tions. For example, using a list of 46 chronic conditions,
we found 99% of the 15,180 theoretically possible combi-
nations of three diseases (“triads”) in a large claims data
set [1]. Over the last decade, many research groups have
tried to understand the complexity of multimorbidity
due to its high prevalence, estimated to affect 50% to 99%
of the older population [2] and its association with adverse
health outcomes, such as functional status decline, lower
quality of life, higher mortality risk, increased health care
utilisation and, therefore, rising health care costs [3,4].
Despite the many studies analysing the associations of
diseases [5,6], it is still unknown how to reduce the com-
plexity of multimorbidity, e.g. in order to permit a more
thorough consideration of multimorbidity in clinical prac-
tice guidelines.
In multimorbidity research, it is often assumed that health
outcomes are mainly influenced by the individual diseases
themselves [7] and that there may be additional effects of
disease interactions. A recent review identifies 14 studies
that try to reduce the heterogeneity of multimorbidity [8],
which can be done in two possible ways. First, one can start
with the full complexity of multimorbidity and identify clus-
ters of diseases that are often diagnosed together (“cluster
method”) [9]. Second, one can start with single diseases and
group them into disease combinations usually based on
prevalence figures (“combination method”) [1].
Both methods have limitations. In using the combination
method, the unit size (e.g. disease triads) does not necessarily
match the number of conditions of a single person so that
there are always more combinations than people in a data
set. Regarding triads, for example, if a person has four dis-
eases he/she will appear four times in the data set. The com-
bination method does not show how combinations overlap
in people, so that it is difficult to infer from combination-
level to person-level. In contrast, using the cluster method,
one cannot determine how diseases are associated within
one cluster. For example, some diseases might only be in the
same cluster because they are linked through a third dis-
ease, e.g. hypertension and renal insufficiency might be
linked through diabetes. As clusters overlap, one might
also ask which diseases serve as a bridge between clusters.
Therefore, this study aims at transcending the cluster
and combination methods in order to depict which dis-
eases are associated with each other on person-level within
the clusters and which ones are responsible for the over-
lapping of multimorbidity clusters.
Methods
Data set
The analyses are based on ambulatory data of the Gmünder
ErsatzKasse, a German statutory health insurance companywith 1.7 million insurants (in 2008), which corresponds to
2.4% of the statutory insured population [10]. In Germany,
about 90% of the total population is insured by statutory
health insurance companies, because there is an obligation
to be part of the statutory insurance system. The only
exceptions are public servants (“Beamte”), clerics, profes-
sional soldiers, self-employed people (except artists and
farmers), and people with an income over 52.000€/year
who decide that they want to leave the statutory health in-
surance system. People in Germany who are not part of
the statutory insurance system can be insured by private
health insurance companies.
The Gmünder ErsatzKasse has a greater proportion of
elderly male insurants than the general population of
Germany, therefore, data analyses have to be adjusted for
gender. The dataset contains pseudonymised data from
every insured member of this company. The sample used
for our analyses consists of all people aged 65 years and
older who were continuously insured throughout the year
2006. The claims data set includes all diseases reported by
ambulatory physicians. All problems managed by physi-
cians within the statutory health insurance system have to
be coded in ICD-10 (International Statistical Classification
of Diseases and Related Health Problems, 10th Revision)
and forwarded to the health insurance companies as regu-
lated by §295(1) of the German Social Security Code SGB
V and §44(3) of the Federal Collective Agreement within
the statutory health insurance system in Germany [11]. As
there is no limit to the number of diagnoses per patient
that can be forwarded to health insurance companies, all
diagnoses by ambulatory physicians are included in the
data set.
The analysis of morbidity was based on a list of 46 de-
fined diagnosis groups of chronic diseases (see below)
derived from ICD-10 codes. The diagnoses were only
counted if they were coded in at least three out of four
quarters (three month periods) in 2006. This criterion was
chosen in order to increase the validity of the diagnoses
based on claims data by avoiding transitory or even acci-
dental diagnoses. Prevalence, gender-specific rank order,
and ICD-10 codes of the diagnosis groups have been pub-
lished in another study [9].
The methods for compiling the list of 46 diagnosis
groups have been described elsewhere in detail [1]. In
short, we used the most frequent conditions documented
in GP surgeries as listed in a panel survey of the Central
Research Institute of Statutory Ambulatory Health Care in
Germany (“ADT-Panel”) [12]. Chronicity of diagnoses was
assessed using the report of the expert group on the im-
plementation of a morbidity oriented risk adjustment
scheme in the German Statutory Health Insurance [13]. In
order to capture a comprehensive picture of the disease
patterns in individual patients, we amended this list by all
chronic conditions with a prevalence ≥ 1% in the age
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Kasse in 2006. ICD-10 codes were grouped together if dis-
eases and syndromes had comparable pathophysiological
mechanisms and if ICD codes of related disorders were
supposed to be used ambiguously by coding physicians in
clinical reality, respectively.
Statistical analyses
The main feature of the statistical methods used in this
study is a network analysis [14] which shows all associa-
tions between the selected diseases in graph format. The
resulting “disease network” shows which diseases are
often diagnosed together and how many associations to
other diseases each disease has. The network analysis in-
corporates information from two previously published
analyses: 1) triads identified by prevalence and observed/
expected ratio [1] and 2) multimorbidity clusters from
factor analysis [9].
The analyses were conducted in the multimorbid popu-
lation, i.e. we included all patients who had at least three
chronic conditions from the list of 46 diagnosis groups.
We performed our analyses for both genders separately,
because there are big differences between males and
females in the prevalence rates of chronic conditions
and we, therefore, wanted to allow for a possibly different
association structure. To determine which diseases were
associated with each other, we started with triads, i.e. com-
binations of three diseases. We used the prevalence as a
criterion for relevance. Triads with a prevalence < 1% in
the data set were excluded. The association between dis-
eases was determined by observed/expected ratios (“O/E-
ratios”). The expected prevalence of triads was calculated
by multiplying the total prevalence of the single diseases
within this triad by each other. The O/E-ratio was then es-
timated by dividing the observed by the expected preva-
lence of the triad. We defined diseases within a triad as
associated with each other when the O/E-ratio was ≥ 2.
For example, if we looked at the combination of hyperten-
sion (prevalence in the multimorbid male population:
69.4%), lipid metabolism disorders (48.0%) and chronic
low back pain (41.0%), we expected a prevalence of 13.7%
(0.694*0.480*0.410 = 0.137). We observed a prevalence of
13.9% for this combination in the data set. Therefore, the
O/E-ratio in this case was 1.01 (0.139/0.137 = 1.01), which
was below 2 and, therefore, the three diseases were not as-
sociated according to our definition and the triad was ex-
cluded from further analyses. The analyses for identifying
relevant and associated triads were conducted using R ver-
sion 3.0.1 [15].
For triads considered as relevant and associated, we ex-
tracted an edgelist, i.e. a list of all disease pairs contained
within the selected triads. The edgelist was used to visual-
ise the disease networks of both genders. The position
of the diseases within the two-dimensional space wascomputed by a multidimensional scaling procedure. These
analyses were conducted with the Stata 12.1 network ana-
lysis module Netplot by Rense Corton [14].
The results from this procedure were grouped (see next
paragraph) using the multimorbidity clusters identified by
factor analysis presented in a previous study [9]. In short,
correlations between diagnosis groups were analysed by
exploratory factor analysis based on a tetrachoric correl-
ation matrix. We used an oblique (oblimin) rotation of
factor loading matrices. The factors that resulted from this
analysis could be interpreted as clusters of diagnosis
groups frequently associated with each other. Factors were
regarded as substantial if they had an eigenvalue of 1.0 or
more. Diagnoses were assigned to a cluster if they had a
factor loading of 0.25 or more on the pattern in charge.
As a next step of the analysis presented here, the single
diseases were grouped into the multimorbidity clusters of
“cardiovascular and metabolic disorders” and “anxiety, de-
pression, somatoform disorders and pain”. The pattern
“neuropsychiatric disorders” was not used as a grouping
variable because we did not find a triad that represented
three diseases from this pattern in either gender. However,
the single neuropsychiatric diseases were still part of the
data analysis. The relation between diseases and the multi-
morbidity cluster they were assigned to was pictured in
two figures based on the Netplot graphs mentioned above.
We also calculated quantitative measures for the dis-
ease networks, which included node degree centrality
(i.e. the number of observed edges of one disease in rela-
tion to the number of possible edges, which was used as a
measure for the connectedness of a disease) and node be-
tweenness centrality (i.e. the number of times that diseases
served as a bridge in the shortest pathway between other
diseases, which was used as a measure for the potential in-
fluence of a disease on the distribution of other diseases in
one person). Additionally, we also calculated the average
node betweenness centrality as a (negative) measure for
the total extent of accumulation of diseases within the net-
works. These analyses were performed by Visone 2.7.3.
In order to provide greater confidence in the study re-
sults, we replicated all analyses with the ambulatory data
of the Gmünder ErsatzKasse from 2004. As the preva-
lence of most chronic conditions was significantly lower
in 2004, we chose to lower the prevalence criterion for
triads from 1.0% to 0.85% in this data set, which resulted
in a comparable number of eligible triads as in 2006. All
other methods, i.e. the methods for data preparation,
factor analyses, extraction of the edgelists, and network
analysis, as well as the O/E-ratio used for triad inclusion,
were the same as in 2006.
Ethics statement
The research presented in this paper was conducted ac-
cording to the principles expressed in the Declaration of
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cause our research was based on insurance claims data and
the data set was analysed anonymously (as regulated by
German law pursuant to §75 SGB X). The study was ap-
proved by the Ethics Committee of the Medical Association
of Hamburg (approval no. PV3057). The approval included
the waiver of consent.
Results
We found a total of 149,280 patients in our 2006 data
set of which 98,619 (66.1%) were defined as multimorbid
because they had 3 or more chronic conditions from our
list of 46 diagnosis groups. The distribution of age, gen-
der, and the number of chronic conditions in the multi-
morbid population is shown in Table 1. 43,632 (44.2%)
of these patients were female and 54,987 (55.8%) were
male. The triads by multimorbidity clusters that had pre-
viously been identified by factor analysis are shown in
Tables 2 and 3. We found 13,460 triads of chronic con-
ditions in the female population of which 932 had a
prevalence ≥ 1% and 57 of these also had an O/E ratio ≥ 2
(cf. Table 2). In the male population, we found 14,105 tri-
ads of which 830 had a prevalence ≥ 1% and 51 of these
also had an O/E ratio ≥ 2 (cf. Table 3). In total, the selected
triads of females consisted of 31 chronic conditions with
200 edges and the selected triads of males included 29
chronic conditions with 174 edges.
The prevalence, the number of edges as well as degree
and betweenness centrality of chronic conditions are
shown in Table 4. In both genders, the condition with
the highest number of edges was chronic low back pain
(16 edges in females and males), i.e. chronic low back
pain was associated with 16 other chronic conditions,
which corresponded to 8.0% of all possible connections
(degree centrality) in females and 9.2% in males. Chronic
low back pain also was the most central disease in the
networks of both genders in terms of being the most im-
portant mediator of connections between other chronic
conditions (betweenness centrality). Another disease
with high betweenness centrality in both genders was
hypertension. Depression also was an important medi-
ator of disease connections in females, but not in males.
The average level of accumulation in the female disease
network (average node betweenness) was 3.2%, while the
male disease network had a slightly higher average nodeTable 1 Age and the number of diagnosis groups by gender
2006
Females
Number of patients 43,632 (44.2%) 5
Age: mean ± sd 73.3 ± 6.8
Chronic conditions: mean ± sd 6.0 ± 2.7
sd = standard deviation; *patients are defined as multimorbid if they have ≥ 3 chronbetweenness of 3.4% and thus was slightly less accumu-
lated than the female disease network.
Figure 1 shows the disease associations in the multi-
morbid female population and Figure 2 shows them in
the multimorbid male population. In these figures, each
ellipse represents a chronic condition and the surface
area of each ellipse is proportional to the prevalence of
the disease. Each line represents an association between
two chronic conditions. For example, the triad “hyper-
tension + urinary incontinence + cancers” in the male
population is represented by three ellipses and the three
lines between these ellipses in the lower right corner of
Figure 2. These figures can be interpreted that two dis-
eases linked by an edge are often diagnosed together on
person-level. For this interpretation, only direct links are
relevant, e.g. in the female population, chronic low back
pain is linked to somatoform disorders and dizziness, but
there is no edge between somatoform disorders and dizzi-
ness. This means that chronic low back pain is often diag-
nosed together with a somatoform disorder, and chronic
low back pain also is often diagnosed together with dizzi-
ness, but the diagnosis of dizziness does not often occur
in conjunction with a somatoform disorder diagnosis.
Our replication analysis in the 2004 data set showed
similar results as in 2006. A total of 123,224 patients were
included in these analyses of which 72,548 were multimor-
bid according to our definition. Age, gender, and the num-
ber of chronic conditions of this population are shown in
Table 1. Regarding the factor analysis, we found a very
similar association structure in 2004 with the same three
clusters extracted for males and females as in 2006. The
only notable difference in the analyses presented here was
that the ADS and pain cluster in the male population of
2004 did not include prostatic hyperplasia and sexual dys-
function. Instead, one additional multimorbidity cluster
with prostatic cancer and related disorders had been ex-
tracted. Except for that, only minor differences between
both years were found in the factor analyses.
In 2004 we found 957 triads with a prevalence ≥ 0.85%
in the female population and 56 of these also had an
O/E ratio ≥ 2. In the male population, we found 819 tri-
ads with a prevalence ≥ 0.85% and 49 of these also had an
O/E ratio ≥ 2. In total, the selected triads of females con-
sisted of 29 chronic conditions with 194 edges and the se-
lected triads of males included 27 chronic conditions within the multimorbid* population of 2006 and 2004
2004
Males Females Males
4,987 (55.8%) 32,369 (44.6%) 40,179 (55.4%)
72.2 ± 5.9 73.6 ± 6.8 72.3 ± 5.9
5.9 ± 2.6 5.7 ± 2.6 5.6 ± 2.5
ic conditions.
Table 2 Triads with a prevalence ≥ 1% and an observed/expected ratio ≥ 2 by multimorbidity clusters in the female
population with ≥ 3 chronic conditions (n = 43.632)
Cardiovascular and metabolic disorders O/E-ratio Prevalence in %
Diabetes mellitus + Hyperuricemia/Gout + Liver diseases 3.8 1.0
Diabetes mellitus + Obesity + Hyperuricemia/Gout 3.7 1.4
Hypertension + Hyperuricemia/Gout + Renal insufficiency 3.7 1.2
Chronic ischemic heart disease + Cardiac arrhythmias + Cardiac insufficiency 3.7 1.1
Lipid metabolism disorders + Hyperuricemia/Gout + Liver diseases 3.1 1.6
Diabetes mellitus + Chronic ischemic heart disease + Cardiac insufficiency 3.0 1.4
Diabetes mellitus + Chronic ischemic heart disease + Neuropathies 2.9 1.0
Lipid metabolism disorders + Cardiac arrhythmias + Cardiac valve disorders 2.8 1.0
Hypertension + Cardiac arrhythmias + Cardiac valve disorders 2.7 1.5
Diabetes mellitus + Chronic ischemic heart disease + Hyperuricemia/Gout 2.7 1.4
Severe vision reduction + Diabetes mellitus + Neuropathies 2.7 1.2
Diabetes mellitus + Chronic ischemic heart disease + Atherosclerosis/PAOD 2.7 1.2
Lipid metabolism disorders + Obesity + Hyperuricemia/Gout 2.6 1.8
Lipid metabolism disorders + Diabetes mellitus + Hyperuricemia/Gout 2.3 3.0
Hypertension + Obesity + Hyperuricemia/Gout 2.3 2.3
Hypertension + Hyperuricemia/Gout + Liver diseases 2.3 1.8
Lipid metabolism disorders + Chronic ischemic heart disease + Cardiac valve disorders 2.3 1.0
Hypertension + Chronic ischemic heart disease + Renal insufficiency 2.2 1.2
Hypertension + Atherosclerosis/PAOD + Cerebral ischemia/Chronic stroke 2.2 1.2
Lipid metabolism disorders + Hyperuricemia/Gout + Cardiac insufficiency 2.2 1.2
Hypertension + Chronic ischemic heart disease + Cardiac insufficiency 2.1 2.6
Lipid metabolism disorders + Chronic ischemic heart disease + Atherosclerosis/PAOD 2.1 1.8
Diabetes mellitus + Chronic ischemic heart disease + Cardiac arrhythmias 2.1 1.5
Hypertension + Diabetes mellitus + Renal insufficiency 2.1 1.5
Diabetes mellitus + Chronic ischemic heart disease + Obesity 2.1 1.3
Lipid metabolism disorders + Obesity + Liver diseases 2.1 1.3
Lipid metabolism disorders + Hyperuricemia/Gout + Atherosclerosis/PAOD 2.1 1.2
Lipid metabolism disorders + Liver diseases + Atherosclerosis/PAOD 2.1 1.0
Hypertension + Diabetes mellitus + Obesity 2.0 4.6
Lipid metabolism disorders + Chronic ischemic heart disease + Hyperuricemia/Gout 2.0 1.9
Hypertension + Chronic ischemic heart disease + Cardiac valve disorders 2.0 1.3
Severe vision reduction + Diabetes mellitus + Atherosclerosis/PAOD 2.0 1.1
Anxiety, depression, somatoform disorders and pain O/E %
Chronic low back pain + Depression + Somatoform disorders 2.6 1.7
Chronic low back pain + Asthma/COPD + Allergies 2.4 1.4
Chronic low back pain + Intestinal diverticulosis + Chronic gastritis/GERD 2.4 1.1
Chronic low back pain + Depression + Insomnia 2.3 1.5
Joint arthrosis + Depression + Somatoform disorders 2.3 1.1
Chronic low back pain + Depression + Dizziness 2.3 1.0
Joint arthrosis + Depression + Insomnia 2.3 1.0
Chronic low back pain + Somatoform disorders + Chronic gastritis/GERD 2.2 1.2
Chronic low back pain + Lower limb varicosis + Hemorrhoids 2.1 1.2
Chronic low back pain + Gynaecological problems + Urinary incontinence 2.1 1.2
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Table 2 Triads with a prevalence ≥ 1% and an observed/expected ratio ≥ 2 by multimorbidity clusters in the female
population with ≥ 3 chronic conditions (n = 43.632) (Continued)
Chronic low back pain + Chronic gastritis/GERD + Insomnia 2.1 1.1
Chronic low back pain + Gynaecological problems + Somatoform disorders 2.0 1.2
Depression + Osteoporosis + Chronic gastritis/GERD 2.0 1.1
Both multimorbidity patterns O/E %
Joint arthrosis + Obesity + Hyperuricemia/Gout 2.5 1.2
Chronic ischemic heart disease + Lower limb varicosis + Cardiac insufficiency 2.5 1.0
Joint arthrosis + Chronic ischemic heart disease + Cardiac insufficiency 2.4 1.5
Chronic low back pain + Hyperuricemia/Gout + Liver diseases 2.3 1.2
Hypertension + Depression + Anxiety 2.2 1.0
Chronic low back pain + Obesity + Hyperuricemia/Gout 2.1 1.5
Diabetes mellitus + Obesity + Lower limb varicosis 2.1 1.5
Joint arthrosis + Diabetes mellitus + Neuropathies 2.1 1.4
Chronic low back pain + Depression + Neuropathies 2.1 1.4
Chronic low back pain + Neuropathies + Chronic gastritis/GERD 2.1 1.2
Joint arthrosis + Obesity + Lower limb varicosis 2.0 2.0
Lipid metabolism disorders + Asthma/COPD + Allergies 2.0 1.1
O/E: observed/expected ratio; PAOD: peripheral arterial occlusive disease; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease.
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ures of disease networks as in 2006 with a clear separation
between the multimorbidity clusters: 1) ADS and pain and
2) cardiovascular and metabolic disorders. Degree and be-
tweenness centrality in the cluster “ADS and pain” were
comparable to 2006, as chronic low back pain also had the
highest degree and betweenness centrality of all nodes and
depression still had the second highest betweenness cen-
trality in females in this cluster. The only notable differ-
ences related to betweenness centrality in the cluster
“cardiovascular and metabolic disorders”, as hypertension
did not constitute an important mediator between chronic
conditions in any gender, but was replaced in 2004 by hy-




This is the first study that uses a systematic approach to
integrate the two current methods to determine multi-
morbidity clusters in the older population and, therefore,
includes information about the association between
single diseases on person-level. It shows epidemiologi-
cally relevant associations between diseases in graph
format and also gives information about the number
of connections of one disease to other diseases as well
as how much potential influence it has on the distribution
of other diseases in one person. This information can
provide a basis for selecting relevant comorbidities
when designing clinical practice guidelines or decidingwhich comorbidity-based treatment recommendations
are relevant.
The chronic condition with the highest number of asso-
ciations was chronic low back pain, which also appeared
to be by far the most important mediator of connections
between other chronic conditions. High numbers of edges
were also found in both genders for joint arthrosis and for
several metabolic (hyperuricemia/gout, diabetes mellitus)
and cardiovascular diseases (hypertension, chronic ischemic
heart disease). The results presented here suggest that out
of these conditions, hypertension is the one that serves as
the most important bridge between other diseases. How-
ever, as our replication analysis shows, this result changes
over time. In the 2004 data set, hyperuricemia/gout (males)
and chronic ischemic heart diseases (females) seemed to
serve as important bridges instead. Among women, depres-
sion was also characterized by many edges and it also
seemed to be mediating many other disease connections. It
should be noted that diseases with a higher prevalence did
not necessarily have a higher degree centrality or between-
ness centrality than diseases with a lower prevalence (e.g. in
the male population, hyperuricemia/gout had only half the
prevalence of lipid metabolism disorders but 50% more
edges and a much higher betweenness centrality).
An association of low back pain with a large number
of chronic conditions had been reported before, e.g. with
cardiovascular diseases [16] as well as psychiatric diag-
noses and pain syndromes [17]. In a previous study, we
found that the prevalence of chronic low back pain in-
creased more than expected by chance with the number
Table 3 Triads with a prevalence ≥ 1% and an observed/expected ratio ≥ 2 by multimorbidity clusters in the male
population with ≥ 3 chronic conditions (n = 54.987)
Cardiovascular and metabolic disorders O/E-ratio Prevalence in %
Obesity + Hyperuricemia/Gout + Liver diseases 3.5 1.3
Chronic ischemic heart disease + Cardiac arrhythmias + Cardiac insufficiency 3.3 1.7
Diabetes mellitus + Atherosclerosis/PAOD + Neuropathies 3.3 1.4
Chronic ischemic heart disease + Cardiac arrhythmias + Cardiac valve disorders 3.2 1.2
Diabetes mellitus + Obesity + Liver diseases 3.0 1.5
Severe vision reduction + Diabetes mellitus + Neuropathies 3.0 1.5
Chronic ischemic heart disease + Atherosclerosis/PAOD + Renal insufficiency 2.9 1.2
Chronic ischemic heart disease + Atherosclerosis/PAOD + Cardiac insufficiency 2.9 1.2
Diabetes mellitus + Atherosclerosis/PAOD + Renal insufficiency 2.6 1.1
Chronic ischemic heart disease + Hyperuricemia/Gout + Renal insufficiency 2.5 1.5
Chronic ischemic heart disease + Cardiac arrhythmias + Renal insufficiency 2.4 1.3
Chronic ischemic heart disease + Atherosclerosis/PAOD + Cerebral ischemia/Chronic stroke 2.4 1.3
Diabetes mellitus + Atherosclerosis/PAOD + Cerebral ischemia/Chronic stroke 2.4 1.2
Hypertension + Renal insufficiency + Cardiac insufficiency 2.4 1.1
Lipid metabolism disorders + Hyperuricemia/Gout + Liver diseases 2.3 3.5
Diabetes mellitus + Hyperuricemia/Gout + Liver diseases 2.3 2.3
Diabetes mellitus + Obesity + Hyperuricemia/Gout 2.3 1.9
Lipid metabolism disorders + Obesity + Liver diseases 2.3 1.7
Diabetes mellitus + Hyperuricemia/Gout + Renal insufficiency 2.3 1.4
Diabetes mellitus + Cardiac arrhythmias + Cardiac insufficiency 2.3 1.2
Hypertension + Urinary incontinence + Cancers 2.3 1.1
Lipid metabolism disorders + Hyperuricemia/Gout + Renal insufficiency 2.2 2.1
Diabetes mellitus + Chronic ischemic heart disease + Cardiac insufficiency 2.2 1.8
Hypertension + Cardiac arrhythmias + Cardiac valve disorders 2.1 1.8
Diabetes mellitus + Chronic ischemic heart disease + Renal insufficiency 2.1 1.7
Lipid metabolism disorders + Cardiac arrhythmias + Cardiac valve disorders 2.1 1.2
Chronic ischemic heart disease + Hyperuricemia/Gout + Cardiac insufficiency 2.1 1.2
Hyperuricemia/Gout + Liver diseases + Atherosclerosis/PAOD 2.1 1.1
Hypertension + Hyperuricemia/Gout + Renal insufficiency 2.0 2.7
Lipid metabolism disorders + Obesity + Hyperuricemia/Gout 2.0 2.7
Hypertension + Obesity + Liver diseases 2.0 2.3
Hypertension + Cardiac arrhythmias + Cardiac insufficiency 2.0 2.3
Diabetes mellitus + Chronic ischemic heart disease + Neuropathies 2.0 1.7
Lipid metabolism disorders + Atherosclerosis/PAOD + Cerebral ischemia/Chronic stroke 2.0 1.6
Chronic low back pain + Cardiac arrhythmias + Cardiac valve disorders 2.0 1.0
Anxiety, depression, somatoform disorders and pain O/E %
Chronic low back pain + Hemorrhoids + Chronic gastritis/GERD 2.5 1.0
Chronic low back pain + Joint arthrosis + Hemorrhoids 2.3 1.6
Chronic low back pain + Prostatic hyperplasia + Sexual dysfunction 2.3 1.2
Chronic low back pain + Joint arthrosis + Lower limb varicosis 2.2 2.5
Chronic low back pain + Joint arthrosis + Intestinal diverticulosis 2.2 1.4
Chronic low back pain + Depression + Chronic gastritis/GERD 2.2 1.1
Chronic low back pain + Prostatic hyperplasia + Hemorrhoids 2.1 1.6
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Table 3 Triads with a prevalence ≥ 1% and an observed/expected ratio ≥ 2 by multimorbidity clusters in the male
population with ≥ 3 chronic conditions (n = 54.987) (Continued)
Chronic low back pain + Joint arthrosis + Insomnia 2.1 1.3
Chronic low back pain + Joint arthrosis + Severe hearing loss 2.1 1.1
Both multimorbidity patterns O/E %
Chronic ischemic heart disease + Asthma/COPD + Cardiac insufficiency 2.5 1.0
Chronic low back pain + Joint arthrosis + Neuropathies 2.2 1.8
Chronic low back pain + Obesity + Liver diseases 2.2 1.4
Chronic low back pain + Atherosclerosis/PAOD + Neuropathies 2.1 1.1
Joint arthrosis + Obesity + Hyperuricemia/Gout 2.0 1.4
Hyperuricemia/Gout + Liver diseases + Asthma/COPD 2.0 1.1
Hyperuricemia/Gout + Prostatic hyperplasia + Renal insufficiency 2.0 1.1
O/E: observed/expected ratio; PAOD: peripheral arterial occlusive disease; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease.
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http://www.biomedcentral.com/1471-2458/14/1285of comorbidities one person had [18]. For this reason,
chronic low back pain might be more often the result of
and not be the cause for other diseases. Low back pain
could also be part of some general frailty pattern [16].
Raspe et al. suggest that back pain undergoes a unidirec-
tional process of chronification towards a complex pain
syndrome including other types of pain as well as func-
tional and emotional impairments [19]. Another explan-
ation might be that chronic low back pain is often found
as a secondary diagnosis when multimorbid patients
consult a physician for other reasons. E.g. Waxman et al.
identified that 71% of patients with back pain did not
see their physician for this reason and that depression
symptoms had a higher impact on consultation rates for
back pain than pain characteristics [20].
As stated above, we also detected a multitude of associa-
tions between disorders that belonged to the metabolic
syndrome (i.e. obesity, hypertension, lipid metabolism dis-
orders and diabetes mellitus [21]), hyperuricemia/gout
and cardiovascular diseases (i.e. hypertension, atheroscler-
osis, chronic ischemic heart disease) in both genders. Such
co-occurrences have been well documented. For example,
the relative excess risk for cardiovascular disease is esti-
mated to be two to eight times higher in people with dia-
betes than in non-diabetic individuals, when adjusted for
age, sex, and ethnicity [22]. A main reason for this associ-
ation might be an overlapping of behavioural and/or gen-
etic risk factors for diabetes and cardiovascular disease
[21]. It has also been implied that diabetes mellitus and
gout share the same risk factors [23].
Multimorbidity clusters
Except for asthma/COPD, we found the same structure
of multimorbidity clusters in the network analysis of tri-
adic disease combinations in both genders as in the pre-
viously published factor analysis [9]. Reasons for these
associations are discussed in the literature. For example,
the association between respiratory and cardiovasculardisease might be due to systemic inflammation, chronic
infections, shared risk factors (such as smoking) or other
undefined factors [24].
The network analysis also showed some associations
within the multimorbidity clusters that were overlooked
by factor analysis. Regarding network analysis, this relates
particularly to neuropathies and severe vision reduction
associated with the multimorbidity cluster of cardiovascu-
lar and metabolic disorders in both genders As both disor-
ders are frequent complications of diabetes mellitus [25],
this seems to be a plausible extension of this pattern. In
females, the pattern of cardiovascular and metabolic disor-
ders was amended by cerebral ischemia/chronic stroke,
which had already been included in this pattern for the
male population in the factor analysis.
We found three reasons for overlapping phenomena
between the multimorbidity clusters cardiovascular and
metabolic disorders and ADS and pain. First, there
might be medical explanations, such as shared risk factors,
causation and complications, e.g. the association between
diseases that constitute the metabolic syndrome and mus-
culoskeletal disorders. There is evidence that obesity and
associated diseases, like diabetes mellitus, might be risk
factors for low back pain [26,27] and osteoarthritis [28,29].
There is also some evidence that anxiety and depression
might lead to hypertension [30] and associated disorders.
A second group of reasons for overlapping multimorbidity
clusters might be related to utilization patterns of the dif-
ferent medical disciplines in ambulatory care. For example,
an urologist consulted for prostatic hyperplasia might
regularly test for renal insufficiency or hyperuricemia and,
therefore, the prevalence of these diagnoses might be
higher in patients with prostatic hyperplasia. Third, there
is no obvious explanation for some associations between
diseases of different patterns, e.g. the triad of cardiac valve
disorders, cardiac arrhythmias and chronic low back pain.
Research is needed to identify the mechanisms for this type
of overlapping if these relations are confirmed.
Table 4 Prevalence, number of edges, degree and betweenness centrality of diseases by gender and multimorbidity
clusters in the population with ≥ 3 chronic conditions
ADS and pain Prevalence in patients Number of edges (degree centrality) Betweenness centrality
Total Females Males Females Males Females Males
Chronic low back pain 43.7% 47.1% 41.0% 16 (8.0%) 16 (9.2%) 28.4% 32.2%
Joint arthrosis 28.7% 33.6% 24.8% 10 (5.0%) 9 (5.2%) 4.9% 5.7%
Lower limb varicosis 16.4% 22.7% 11.5% 7 (3.5%) 2 (1.1%) 3.1% 0.0%
Prostatic hyperplasia * - 28.1% - 5 (2.9%) - 2.6%
Asthma/COPD 15.3% 14.1% 16.3% 3 (1.5%) 4 (2.3%) 0.4% 0.1%
Depression 12.4% 18.1% 7.8% 10 (5.0%) 2 (1.1%) 11.9% 0.0%
Chronic gastritis/GERD 10.8% 10.8% 10.8% 7 (3.5%) 3 (1.7%) 2.7% 0.1%
Osteoporosis 10.7% 19.7% 3.6% 2 (1.0%) - 0.0% -
Gynaecological problems * 16.6% - 3 (1.5%) - 0.1% -
Allergies 7.3% 8.5% 6.3% 3 (1.5%) - 0.4% -
Insomnia 6.6% 7.6% 5.8% 4 (2.0%) 2 (1.1%) 0.2% 0.0%
Intestinal diverticulosis 6.3% 6.4% 6.2% 2 (1.0%) 2 (1.1%) 0.0% 0.0%
Hemorrhoids 6.1% 5.2% 6.8% 2 (1.0%) 4 (2.3%) 0.0% 0.4%
Somatoform disorders 5.9% 7.7% 4.5% 5 (2.5%) - 1.1% -
Severe hearing loss 4.6% 3.8% 5.2% - 2 (1.1%) - 0.0%
Dizziness 4.2% 5.4% 3.4% 2 (1.0%) - 0.0% -
Anxiety 2.5% 3.7% 1.6% 2 (1.0%) - 0.0% -
Sexual dysfunction * - 4.5% - 2 (1.1%) - 0.0%
Cardiovascular and metabolic
Hypertension 69.3% 69.3% 69.4% 13 (6.5%) 9 (5.2%) 12.0% 12.0%
Lipid metabolism disorders 47.4% 46.7% 48.0% 11 (5.5%) 8 (4.6%) 5.8% 1.4%
Diabetes mellitus 28.5% 24.9% 31.4% 14 (7.0%) 11 (6.3%) 5.8% 5.0%
Chronic ischemic heart disease 25.7% 18.2% 31.6% 13 (6.5%) 10 (5.7%) 5.1% 2.8%
Hyperuricemia/Gout 18.1% 11.3% 23.5% 11 (5.5%) 12 (6.9%) 5.2% 7.8%
Cardiac arrhythmias 18.0% 15.5% 20.0% 6 (3.0%) 8 (4.6%) 0.2% 4.3%
Atherosclerosis/PAOD 13.7% 10.3% 16.4% 8 (4.0%) 10 (5.7%) 2.6% 5.7%
Obesity 12.4% 13.4% 11.7% 9 (4.5%) 7 (4.0%) 2.2% 3.8%
Liver diseases 12.0% 9.9% 13.7% 7 (3.5%) 8 (4.6%) 2.0% 4.5%
Cardiac insufficiency 9.0% 10.1% 8.1% 8 (4.0%) 8 (4.6%) 1.0% 1.3%
Cerebral ischemia/Chronic stroke 9.0% 7.3% 10.3% 2 (1.0%) 4 (2.3%) 0.0% 0.1%
Neuropathies 8.2% 8.1% 8.2% 7 (3.5%) 6 (3.4%) 4.6% 3.9%
Renal insufficiency 6.5% 4.2% 8.3% 4 (2.0%) 9 (5.2%) 0.0% 2.6%
Cardiac valve disorders 5.7% 5.2% 6.0% 4 (2.0%) 5 (2.9%) 0.1% 2.2%
No multimorbidity pattern
Severe vision reduction 20.6% 22.0% 19.6% 3 (1.5%) 2 (1.1%) 0.1% 0.0%
Cancers 18.4% 14.8% 21.2% - 2 (1.1%) - 0.0%
Urinary incontinence 5.1% 7.1% 3.5% 2 (1.0%) 2 (1.1%) 0.0% 0.0%
ADS: Anxiety, depression and somatoform disorders; PAOD: peripheral arterial occlusive disease; COPD: chronic obstructive pulmonary disease; GERD: gastro-esophageal
reflux disease; *gender-specific disease.
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Diseases seem to be more associated to each other in the fe-
male population (with 15% more edges and a slightly lower
average node betweenness) than in the male population.This phenomenon can be partly explained by an 11% higher
number of triads with a prevalence ≥ 1% in females than in
males. However, we generally found a comparable disease
network in both genders. In the cluster of cardiovascular
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http://www.biomedcentral.com/1471-2458/14/1285and metabolic disorders, we found a high concordance be-
tween both genders. Females and males both had diabetes
mellitus, chronic ischemic heart disease and hyperuricemia/
gout among the five most associated diseases and compar-
able disease associations in this cluster.
Gender differences were more prominent in the multi-
morbidity cluster of ADS and pain. Although chronic low
back pain and joint arthrosis were the two most associated
diseases in both genders, women generally had more asso-
ciations with psychiatric/psychosomatic disorders, e.g. the
diagnoses anxiety and somatoform disorders were only
present in the disease matrix of the female population.
This also applied for cases of depression which had a com-
parably high degree and betweenness centrality in females,
but not in males. The main reason for these differences
might be due to gender-dependent prevalence rates, e.g. the
prevalence of depression was more than twice as high in
the female than in the male population in our study. These
gender-differences related to depression are confirmed
by a wide range of other studies [31]. Although some-
times influenced by artefacts, like reporting bias, gender-
differences in depression can be considered to be a genuine
phenomenon [21].
Strengths and weaknesses
This study used a network analysis to combine results
from factor analysis and observed/expected ratios of disease
combinations in order to create a pattern-specific disease
network. The methods were well matched as multimorbid-
ity clusters from factor analysis could also be found in the
network analysis and some diseases were identified that
had been overlooked by factor analysis. The figures pro-
vided a systematic overview of all disease associations that
were prevalent and more frequent than expected by chance.
The analyses were based on triads of diseases because mul-
timorbidity was defined by a three disease criterion. For this
reason, associations that occurred only between two dis-
eases were not considered.
A strength of our approach lies in the comprehensive
selection of diseases by including all highly prevalent
chronic conditions (≥1% in the age group 65+) into our
diagnosis groups and applying them to our disease matrix.
Unfortunately, a more recent data set than 2006 was not
available for these analyses. However, we assume that the
associations between diseases that we found are, for the
most part, stable over time, thus results based on newer
data will probably be similar. To provide more confidence
in our results, we did a replication analysis with the 2004
data set of the same insurance company, which used the
same methods as our 2006 analyses, except for a lowered
prevalence criterion for triad inclusion. The reason for this
decision was a much higher prevalence of the most chronic
conditions in 2006 compared to 2004, probably due to
changes in the documentation behaviour of ambulatoryphysicians. This phenomenon had been reported before,
e.g. Uijen and Lisdonk found a 60% increase in the num-
ber of diagnoses of chronic conditions in the Netherlands
between 1985 and 2005 [32]. This trend could probably
also be observed if a more recent data set was used, which
might mean that the prevalence criterion for triad in-
clusion needed to be increased in later years in order
to keep results comparable. Our replication analysis con-
firmed the results presented here. However, there are gen-
erally great differences concerning the identification
of multimorbidity clusters in different studies [8], so
that there is still need for replication in other countries
and populations.
It should also be noted that the study is based on diagno-
ses and not on diseases. Although accidental and transitory
diagnoses were excluded, in some cases, diagnoses might
be imprecise, ambiguous, or incomplete because they were
not clinically verified by trained professionals. This is a
general problem with insurance claims data [33], but in
our view, the benefits of claims data outweigh their disad-
vantages: We are provided with a large unselected popula-
tion group, representing real-world conditions, including
people living in protected institutions/nursing homes, as
well as frail individuals, and the oldest-old, i.e. groups of
patients frequently not included in survey and field stud-
ies. In choosing insurance claims data, we also avoided se-
lection bias concerning service providers, and there is no
recall bias concerning diagnosis data. However, as results
from multimorbidity studies might differ depending on
the data set used [34], a replication of our study using
other data sources should also be useful.
Conclusion
Using the current methods for analysing associations be-
tween diseases, we knew the clustering of diseases and fre-
quent disease combinations, but we missed the complete
picture of multimorbidity, because the internal structure
of the clusters and the linking between disease combina-
tions and clusters were still unknown. The results pre-
sented here constitute the first attempt to respond to this
academic vault. We are able to show which diseases are
associated with each other in our data set, to which multi-
morbidity clusters the diseases are assigned and which
diseases are responsible for overlapping multimorbid-
ity clusters.
However, we have to keep in mind that this approach
focuses on statistically selected diseases and that most pa-
tients suffer from more diseases than those represented in
our analyses. For this reason, multimorbidity cannot be
grasped completely. Nevertheless, our methodological ap-
proach might prove a good starting point for further ana-
lyses and guideline developers might find our approach
useful as a basis for discussing which comorbidity should
be addressed in clinical practice guidelines.
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Betweenness centrality: Measure for the potential influence of a disease on
the distribution of other diseases in one person. Defined as the number of
times a disease serves as a bridge in the shortest pathway between two
other diseases in relation to the total number of diseases in the network.
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crossed to get in the shortest pathway from one disease to another disease
if there is no direct association between these diseases.
Degree centrality: Measure for the connectedness of a disease. Defined as
the number of associations of one disease with other diseases in relation to
the total number of diseases in the network.
Edge: Disease pair/association between two diseases. Diseases are defined to
be associated if they are part of a disease triad with a prevalence ≥ 1% and
an observed/expected-ratio is ≥ 2.
Edgelist: A list of all disease pairs contained within the selected triads.
Multimorbidity cluster: Group of diseases that often occur together.
Multimorbidity clusters are determined by tetrachoric factor analysis.
Node: Element of the network analysis. In the analyses presented here,
diseases are used as nodes.
Observed/expected ratio: Measure for the excess prevalence of a disease
combination which is used to determine if there is an association between
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of a disease combination and the product of the prevalences of all single
diseases within this combination.
Triad: Combination of three diseases found in the data set.
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